Abstract: Provided are an ocular surface drug-retaining agent that enables an excellent improvement in retainability of a medicament on an ocular surface and an eye drop containing the agent. An ocular surface drug-retaining agent containing a copolymer having three different kinds of constituent units at a specific ratio can express an excellent effect of retaining a medicament on an ocular surface (in particular, a corneal surface) to allow the effect or action of the drug to be sustained over a long period of time.

Abstract: A method for fabricating a collagen bio-ink includes steps as follows. A first component is provided, wherein the first component is to fill a collagen powder to a first syringe. A second component is provided, wherein the second component is to fill a neutral solution or an acid solution to a second syringe. A mixing step is performed, wherein the first syringe is connected to the second syringe with a Lure lock connector and pushing back and forth to mix the first component and the second component to form a hydrogel and become a collagen bio-ink.

Abstract: The invention relates to functionalized polymers, a process for producing functionalized polymers and the use of functionalized polymers, especially in the field of personal care.

Abstract: The present application relates to a composition for topical application comprising baicalin and/or at least one derivative thereof or an extract containing same, and at least one acrylic polymer, and to the use of said composition in the cosmetics and dermatology fields and in particular for caring for, for the hygiene of, for protecting and/or for making up bodily or facial skin, or for hair care, preferably for caring for bodily or facial skin. A subject of the invention is also a process for the cosmetic treatment of keratin materials, which consists in applying to the keratin materials a composition as defined above, and also the use of said composition in the cosmetics or dermatology field, and in particular for caring for, protecting and/or making up bodily or facial skin, or for hair care, preferably for caring for bodily or facial skin.

Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Abstract: The purpose of the present invention is to newly provide a method with which it is possible to appropriately evaluate the protective effect of an external preparation for skin such as a sunscreen cosmetic, particularly to evaluate how a UV-ray protective effect is affected by heat. This evaluation method is characterized by including (1) a step for forming a coating film of an external preparation for skin on a substrate, (2) a step for heat-treating the coating film of the external preparation for skin, and (3) a step for measuring the UV-ray protective effect of the heat-treated coating film of the external preparation for skin. The heat treatment is preferably carried out for at least one minute at a temperature of 30-70° C.

Abstract: The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

Abstract: The present invention addresses a problem of providing a high quality seamless capsule, with excellent uniformity of shell thickness and virtually no eyes in the shell. The problem can be solved by manufacturing a seamless capsule using a shell composition comprising at least one polysaccharide selected from the group consisting of agar, carrageenan and gellan gum, and a PVA copolymer comprising the following structural units: (i) polyvinyl alcohol, (ii) at least one unsaturated carboxylic acid selected from the group consisting of acrylic acid, methacrylic acid, fumaric acid and maleic acid, and (iii) at least one unsaturated carboxylic acid ester selected from the group consisting of compounds represented by formula [I]: H2C?C(R1)—COOR2??[I] (wherein R1 represents a hydrogen atom or a methyl group, and R2 represents an alkyl group having 1 to 4 carbon atoms).

Abstract: It is provided a coating composition comprising an ionic liquid, and a crosslinked polymeric ionic liquid, wherein the crosslinked polymeric ionic liquid and the ionic liquid are not linked through covalent bonds, and wherein the crosslinked polymeric ionic liquid is linked to a substrate surface. It is also provided a process for its preparation, as well as an article of manufacture at least in part coated with the coating composition as defined above.

Abstract: The invention relates to intravaginal devices, in particular rings, comprising progesterone in a particular polymorphic purity, methods for making such devices and therapeutic uses of said devices. In particular, the intravaginal devices comprise a high amount of progesterone polymorph I and are useful in the treatment of infertility in a female subject.

Abstract: The present invention is directed to a composition of temporary crown materials, comprising a powder reagent and a liquid reagent; wherein the powder reagent comprises PMMA and an initiator, and the liquid reagent comprises MMA, a catalyst, and a plasticizer; wherein the plasticizer is a citrate ester compound. The composition of temporary crown materials of the present invention has high hardness, high toughness, high flexural strength and excellent biocompatibility.

Abstract: The invention relates to protein nanocapsules that exhibit material properties that change in different in vivo environments. A zwitterion moiety on the surface of the nanocapsule can protect the protein from opsonization in a first environment, yet uncouples from the protein nanocapsule in a second environment (e.g. at a pH of less than 6.5). In embodiments of the invention, the uncoupled protein nanocarrier is then internalized by mammalian cells (e.g. tumor cells).

Abstract: The invention provides oral liquid midodrine formulation and uses thereof.

Abstract: A composition including a polymer including at least one of an amic acid structural unit and an imide structural unit and an inorganic particle surface-treated with a compound represented by Chemical Formula 1, a polymer-inorganic particle nanocomposite prepared using the composition an article and an optical device including the article: In Chemical Formula 1, R1 to R4 are independently a C1 to C30 alkyl group, a C3 to C10 cycloalkyl group, a C6 to C30 aryl group, or a combination thereof, and n is an integer of 1 or more.

Abstract: The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.

Abstract: The present invention discloses a sulfonate lycine type hydrophobic associated polymer and a preparation method thereof. A preparation process of the sulfonate lycine type hydrophobic associated polymer comprises the following steps: firstly, mixing acrylamide and acrylic acid in an aqueous solution; adjusting pH of the system to be around 6 to 8; adding 3-(dimethylamino propyl methacrylamide) propanesulfonate, N-aryl-N-alkyl (methyl) acrylamide and lauryl sodium sulfate and stirring till the solution is clear; and after nitrogen is introduced for deoxidization, adding a photoinitiator azobis (isobutylamidine hydrochloride) for performing polymerization under photoinitiation conditions.

Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

Abstract: Provided is a composition, notably a fabric conditioning composition, comprising (a) a quaternary ammonium compound; (b) a cationic polysaccharide; (c) a first non-ionic polysaccharide; and (d) a second non-ionic polysaccharide, wherein the second non-ionic polysaccharide is different from the first non-ionic polysaccharide and the second non-ionic polysaccharide has a Molar Substitution (MS) in the range of 0.2 to 1.8.

Abstract: Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease.

Abstract: A dual reactivity crosslinking agent of formula I having at least two different reactive sites, and hydrogel materials prepared from at least two monomers with different rates of free-radical polymerization reactivity. The crosslinking agent includes at least one free-radical reactive site for vinyl-containing monomer and at least one free-radical reactive site for meth(acrylic)-containing monomer. The hydrogel materials are useful in the manufacture of biocompatible medical devices, for example, hydrogel materials having desirable physical properties useful as contact lens materials.

Abstract: Hydrophobically and hydrophilically modified polysaccharides and methods of using the same for treatment of a subterranean formation. A method of treating a subterranean formation. The method includes obtaining or providing a composition including a hydrophobically and hydrophilically modified polysaccharide (HHMP). The method includes placing the composition in a subterranean formation.

Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Abstract: A cross-linked anionic polyelectrolyte resulting from the polymerization, for 100 mol %: (i) of a proportion no smaller than 30 mol % and smaller than 99.5 mol % monomer units from a monomer having a partially or totally salified strong acid function; (ii) of a proportion no smaller than 0.5 mol % and no greater than 5 mol % monomer units from at least one monomer having Formula (I): CH2?CH(CH3)—C(=0)—OR1 (I), wherein Ri is an alkyl radical including 6 to 18 carbon atoms; (iii) of a proportion greater than 0 mol % and no greater than 5 mol % monomer units from at least one diethylene or polyethylene cross-linking monomer; and (iv) optionally, of a proportion smaller than 69.5 mol % monomer units from a neutral monomer. Also, a method for preparing the polyelectrolyte and to the use thereof as a thickener in topical compositions.

Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.

Abstract: A cosmetic or dermatological compositions of oil-in-water emulsion type, including, in a physiologically acceptable medium, at least gemini surfactant of formula (I): in which R1 and R3 denote, independently of one another, an alkyl radical containing from 1 to 25 carbon atoms; R2 denotes a spacer consisting of a linear or branched alkylene chain containing from 1 to 12 carbon atoms; X and Y denote, independently of one another, a group —(C2H4O)a—(C3H6O)bZ; n ranges from 1 to 10, in combination with an effective amount of at least one semi-crystalline polymer which is solid at ambient temperature and which has a melting point below 70° C., said polymer having a number-average molecular mass greater than or equal to 2000, said emulsion having a proportion of fatty phase of greater than 10% by weight relative to the total weight of the composition and including more than 40% by weight of non-volatile oil(s) relative to the weight of the fatty phase.

Abstract: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the tympanic membrane in a flowable form and, after delivery to the tympanic membrane, becomes sufficiently viscous such that the pharmacologic agent is localized against the tympanic membrane. Such compositions can be used to prophylactically and/or therapeutically treat middle and inner ear conditions, including otitis media.

Abstract: Disclosed embodiments concern a soluble functionalized nanoparticle suitable for use with polymerizable components, such as monomers (or polymers thereof), used to make gradient optical polymer nanocomposites. In particular disclosed embodiments, the nanoparticle is functionalized with one or more surface ligands that promote the solubility and dispersion of the nanoparticle in the disclosed monomer. Also disclosed herein are embodiments of a method for making the functionalized nanoparticle as well as embodiments of a composition comprising the functionalized nanoparticles.

Abstract: Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.

Abstract: The invention relates to an extract of Euodia suaveolens Scheff. The invention is characterized in that the extract is obtained from the airborne portions of the plant by means of at least one extraction step using an organic or hydro-alcoholic solvent, and in that it comprises evodone at a concentration of between 0.1 and 35% by weight of the total weight of the extract, and in that it has an insect repellent activity. The invention also relates to a repellent composition, characterized in that it comprises, in a cosmetically acceptable medium, evodone at a concentration of between 0.1 and 25% by weight of the total weight of the composition, and to the use of evodone as an active agent for repelling insects, in particular mosquitoes and more particularly the European/Mediterranean mosquitoes of the Aedes aegypti species.

Abstract: Contact lenses comprising phosphorylcholine groups release beneficial polyionic or guanidinium-containing agents.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and diclofenac.

Abstract: The present invention aims to provide a method of producing a PTFE aqueous dispersion which contains PTFE particles having a small particle size and which is excellent in dispersion stability by multistage polymerization without using a long-chain fluorosurfactant. The method includes the steps of: (1) polymerizing a fluoromonomer in an aqueous medium in the presence of a fluorosurfactant and a polymerization initiator to provide an aqueous dispersion containing particles of at least one fluoropolymer selected from the group consisting of PTFE and melt-processible fluororesins excluding polytetrafluoroethylene; and (2) polymerizing TFE alone or TFE and a modifying monomer in an aqueous medium in the presence of the fluoropolymer particles and a polymerization initiator to provide an aqueous dispersion containing PTFE particles. The fluoropolymer particles have an equivalent weight (EW) of 6,000 or more and a volume average particle size of not smaller than 0.1 nm but smaller than 20 nm.

Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil and (B) sesame oil. According to the aqueous ophthalmic composition of the present invention, defoaming time is reduced, preservative efficacy is enhanced and photostability is improved.

Abstract: Provided is a rapid release tablet excellent in binding capability and disintegrability and also excellent in storage stability and the like. More specifically, provided are a granulated composite comprising low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight and D-mannitol, wherein the D-mannitol contains 0.9% by weight or less of D-sorbitol; a rapid release tablet comprising the granulated composite and a drug; and a method for producing a granulated composite comprising the steps of: mixing low-substituted hydroxypropyl cellulose having a degree of hydroxypropoxy substitution of from 5 to 16% by weight, first D-mannitol, and water to obtain an aqueous dispersion, and granulating while adding the aqueous dispersion to second D-mannitol, wherein the first D-mannitol and the second D-mannitol contain 0.9% by weight or less of D-sorbitol in total.

Abstract: A macroparticle pigment powder and methods of making the same. The macroparticle pigment powder comprises a plurality of macroparticle particles. The macroparticles are comprised of a matrix material that include pigment particles. In some embodiments the matrix material is polymeric in nature and selected from the group consisting of a natural latex, acrylics, polyacrylate, polymethacrylate, polyurethane, polyvinyl acetate, styrene-butadiene rubber, acrylonitrile butadiene styrene copolymer, and combinations thereof.

Abstract: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.

Abstract: An agricultural oil-based suspension formulation comprising an active ingredient suspended in finely divided form in an oil and at least one unsaturated rubber-type copolymer or a mixture thereof, wherein the rubber-type copolymer comprises at least styrene as a residue.

Abstract: Disclosed is a self-reversible reverse latex including: a) 25-80% by mass of a cross-linked anionic polyelectrolyte (P), resulting from the polymerisation, for 100 mole percent: i)—of a molar proportion 30% and 95% of monomeric units from at least one monomer including a free, partially- or totally-salified strong acid function; and ii)—of a molar proportion >0% and <5% of at least one monomer with diethylenic or polyethylenic crosslinking; b) 0.5-10% by mass of a terpolymer of stearyl methacrylate, pentacosaethoxylated behenyl methacrylate and N,N-dimethylacrylamide, resulting from the polymerisation, for 100 mole percent: of 80-95 mole percent of stearyl methacrylate, of 2.5-10 mole percent of N,N-dimethylacrylamide, and of 2.5-10 mole percent of pentacosaethoxylated behenyl methacrylate, c) 5-40% by mass of at least one oil, and d) 0.1-40% by mass of water; method of preparing same and use thereof as a thickener.

Abstract: The present invention relates to aqueous insecticidal preparations in the form of an aqueous dispersion of finely divided polymer particles which comprise at least one insecticidal organic active ingredient with a solubility in water of not more than 5 g/l at 25° C. at 1013 mbar and which have a mean particle size, determined by dynamic light scattering, of not more than 300 nm, where the polymer particles which comprise the at least one insecticidal active ingredient of a cationic surface charge and where the aqueous dispersion of the active-ingredient-comprising polymer particles is obtainable by subjecting a monomer composition of ethylenically unsaturated monomers M, in which the ethylenically unsaturated monomers M comprise the at least one insecticidal active ingredient in dissolved form, to radical aqueous emulsion polymerization.

Abstract: The invention relates to a composition comprising (1) at least one polar modified polymer, (2) at least one compound selected from a hyperbranched polyol having at least two hydroxyl groups, a sugar silicone surfactant, and a gelling agent.

Abstract: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.

Abstract: The subject invention relates to a method of preparing a biocompatible polymer comprising epsilon-linked L-lysine having free alpha-amino and carboxy functions. The invention further encompasses the resulting biocompatible polymer and articles made from the polymer, in particular contact and intraocular lenses.

Abstract: A method for producing polymerizable solution which comprises dissolving an ethylenically unsaturated zwitterionic monomer in a co-monomer system comprising a functionalized ethylenically unsaturated monomer in which the zwitterionic monomer is soluble, a siloxane group-containing monomer or macromer, and a crosslinking agent is disclosed. The polymerizable solution is biocompatible and can be used to produce polymers and articles such as contact lenses.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: The invention relates to alkoxylation products, their preparation, compositions comprising the alkoxylation products of the invention, and the use thereof as or for producing adhesives and sealants.

Abstract: The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.

Abstract: The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same.

Abstract: The present invention relates to a molded article which is shaped of a polymer composition comprising 100 parts by weight of an olefin-based polymer, and 0.01 to 100 parts by weight of a C10-90 saturated chain hydrocarbon and/or liquid paraffin and 0.01 to 200 parts by weight of a releasable active compound per 100 parts by weight of said olefin-based polymer, and which is drawn at a draw ratio of 2 or more.

Abstract: The present invention describes, in one aspect, the use of two oppositely charged surfactants as the primary emulsifiers in two separated parts of a product. The emulsifiers are chosen such that when the two parts of the emulsion product are mixed, the emulsifiers react to form water insoluble compounds that are no longer able to function as emulsifiers, thus, the oil phase of the emulsion is precipitated onto the skin along with the emulsifier reaction product. Since none of the deposited materials are water soluble, or capable of functioning as emulsifiers, the deposited oil phase is extremely resistant to being washed off. This technology finds applications in hand and body creams and lotions, baby care products, sunscreens, skin protective products, makeup systems, and automotive and furniture polishes.